单独使用 levetiracetam 对儿童患者甲状腺功能的影响
Gulcan Seymen1, Busra Isin Kutlubay2
1Department of Pediatric Endocrinology, Umraniye Training and Research Hospital, Istanbul, Türkiye.
Northern clinics of Istanbul
|January 23, 2026
概括
在儿童的单一治疗中,利维 (LEV) 单一治疗显示,甲状腺刺激激素 (TSH) 水平在12个月内略微,统计学上显著增加. 然而,这些变化在临床上是微不足道的,表明LEV对儿科患者的甲状腺功能是安全的.
科学领域:
- 儿科神经学 儿科神经学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 儿童通常需要长期使用抗药物 (AED) 治疗.
- 甲状腺抑制剂的内分泌作用是一个关键的考虑因素,特别是甲状腺功能.
- 关于AEDs对小儿甲状腺功能的影响的数据有限,特别是对于Levétiracetam (LEV),是有限的.
研究的目的:
- 评估LEV单疗对患有的儿童甲状腺功能的影响.
- 评估甲状腺刺激激素 (TSH) 和自由甲状腺素 (fT4) 水平的变化.
- 为了确定任何观察到的甲状腺功能改变的临床意义.
主要方法:
- 对100名儿科患者进行了回顾性观察性研究,他们接受了至少12个月的LEV单疗法.
- 测量TSH和FT4水平在基线和3,6和12个月.
- 使用配对t测试进行统计分析 (p<0.05显著性).
主要成果:
- 平均TSH水平显示,从基线到12个月的时间 (p=0.0017) 从统计学上显著增加.
- TSH水平保持在正常范围内;没有观察到临床显著的甲状腺功能低下症.
- 自由甲状腺素 (fT4) 水平没有显示统计学上显著的变化,在12个月的边界上升 (p=0.05).
结论:
- 在儿科患者中,单一治疗LEV并没有显著影响甲状腺功能.
- 观察到的TSH增加在统计学上是显著的,但在临床上是微不足道的.
- 在儿童甲状腺功能方面,LEV似乎是一种安全的AED选择;建议进行进一步的前性研究.
相关概念视频
01:18Functions of Thyroid Hormones
5.1K
The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
5.1K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
214
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
271
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
271
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
199
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
199
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
260
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
260
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
192
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
192